Gil Blum, an analyst from Needham, maintained the Buy rating on Mereo Biopharma Group Plc. The associated price target remains the same with $5.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gil Blum’s rating is based on several key factors that suggest a positive outlook for Mereo Biopharma Group Plc. The company’s ongoing Phase III Orbit and Cosmic studies are progressing as planned, with final results expected by the end of 2025. These studies are crucial as they involve patients who have been on therapy for at least 18 months, and the analysis is significantly powered to detect positive outcomes. The relationship between increased bone mineral density and reduced fractures with the use of anti-sclerostin further supports a favorable study result.
Additionally, Mereo Biopharma’s strategic initiatives contribute to the Buy rating. The company is actively seeking a partner for its drug alvelestat, which could enhance its market position. Furthermore, Mereo has retained European rights for vantictumab, a promising treatment for autosomal dominant osteopetrosis type 2, being developed with partner āshibio. Financially, Mereo is in a strong position, ending the third quarter of 2025 with $48.7 million in cash, which is expected to support operations until 2027.
Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Rocket Pharmaceuticals, and Taysha Gene Therapies. According to TipRanks, Blum has an average return of 4.7% and a 39.76% success rate on recommended stocks.